Ribonucleotide reductase inhibitors, as their name implies, are a class of medications that act by blocking an enzyme called ribonucleotide reductase. They are mainly used as anticancer agents that target a specific phase of the cell cycle.
At a quick glance, the life of a cell - its cell cycle - has an interphase, made up of subphases G1, S, and G2, during which the cell is preparing for division; and mitosis, during which the cell actively divides.
Now, a single chromosome is made up of a single DNA molecule that has two strands, which wrap around one another to form a double helix.
Each single strand of DNA is composed of a sequence of DNA nucleotides.
Now, nucleotides are the building blocks of nucleic acids such as deoxyribonucleic acid, or DNA; and ribonucleic acid, or RNA.
The most basic structure of the nucleotide can be broken down into three subunits; a five carbon sugar, a phosphate group, and a nitrogenous base, also known as a nucleobase.
The five carbon sugar is either deoxyribose in DNA or ribose in RNA.
Now, the nucleobases can be either pyrimidines or purines.
The 3 pyrimidine bases are cytosine, or C; thymine, or T, which is DNA specific; and uracil, or U, which is RNA specific.
There are also two purine bases, adenine, or A; and guanine, or G.
Now, if we link up just the sugar and the nucleobase, we’ve got ourselves a nucleoside.
To make a nucleotide, all we’ve got to do is add a phosphate group to the 5th carbon of the sugar on a nucleoside.
Okay, so in order to make DNA nucleotides we use RNA nucleotides.
RNA nucleotides are usually in the monophosphate form and we need to change them into the diphosphate form for DNA.
So a cytoplasmic enzyme called ribonucleotide reductase, also known as ribonucleoside diphosphate reductase, will reduce the ribose within them into deoxyribose, creating deoxyribonucleotides, which then travel to the nucleus where DNA synthesis takes place.
Alright, now the cancer cells are going through the phases of the cell cycle like normal cells, but they divide much more frequently.
Therefore, cancer cells replicate their DNA all the time and they need more deoxyribonucleotides for this process.
This makes them more sensitive to cytotoxic medications like the ribonucleotide reductase inhibitors, since they decrease the amount of available deoxyribonucleotides.
There are also normal tissues that divide rapidly like bone marrow and hair follicles, which explains why these medications are more toxic to these tissues.
Let’s start with hydroxyurea, also known as hydroxycarbamide, which is administered orally.
Hydroxyurea binds to the iron molecules in ribonucleotide reductase, which prevents the enzyme from functioning.
Hydroxyurea is used for myeloproliferative disorders, a group of disorders characterized by proliferation of the bone marrow cells from the myeloid lineage, like chronic myelogenous leukemia and polycythemia vera.
Hydroxyurea is also used for sickle cell disease because it stimulates the production of fetal hemoglobin, or HbF, although the exact mechanism remains uncertain.
Side effects include severe myelosuppression, presenting as leukopenia, macrocytic anemia, and occasionally thrombocytopenia.
Other side effects include gastrointestinal disturbances, pneumonitis, and mild skin reactions.
Hydroxyurea is also associated with minimal teratogenic effects but its safety during pregnancy is not yet determined.
Next is fludarabine phosphate, which is a fluorinated and phosphorylated analog of the antiviral agent vidarabine.
It can be administered either intravenously or orally.
- "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
- "Rang and Dale's Pharmacology" Elsevier (2019)
- "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
- "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
- "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
- "Purine nucleoside analogs in indolent non-Hodgkin's lymphoma" Oncology (Williston Park, NY) (2000)
- "Ribonucleotide reductases: radical enzymes with suicidal tendencies" Chemistry & Biology (1995)
- "Myeloproliferative disorders" Clinical Medicine (2005)